biostudies-literatureUnknown5(4)Chai KLSerious infection is common in patients with multiple myeloma due to immune deficiency from the underlying disease and/or its treatment. Immunoglobulin replacement is one approach to reduce infection risk in these patients. However, few real-world data exist on its use in patients with myeloma. We investigated immunoglobulin use in Australia, New Zealand and Asia-Pacific using registry data and explored its association with survival outcomes. A total of 2374 patients with a median follow-up time of 29.5 months (interquartile range 13.3-54.3 months) were included in the analysis - 1673 from Australia, 313 Korea, 281 New Zealand and 107 Singapore. Overall, 7.1% of participants received immunoglobulin replacement within 24 months of diagnosis. Patients who received immunoglobulin replacement EJHaem690-697https://www.ebi.ac.uk/biostudies/studies/S-EPMC11327709biostudies-literatureVariation in immunoglobulin use and impact on survival in myeloma.PMC11327709Chng WJMoore EMAugustson BMMcCaughan GJKim KYoon SSHarrison SJTso ACThao LMurphy NWong KSTan XNCooke RWellard CKing THocking JMcQuilten ZKAoki NMorrissey COForsyth CJMollee PWood EMSpencer AGoh YTKim JSQuach HHamad NKerridge IChai KLBlacklock HHo PJBapat AfalseVariation in immunoglobulin use and impact on survival in myeloma.Serious infection is common in patients with multiple myeloma due to immune deficiency from the underlying disease and/or its treatment. Immunoglobulin replacement is one approach to reduce infection risk in these patients. However, few real-world data exist on its use in patients with myeloma. We investigated immunoglobulin use in Australia, New Zealand and Asia-Pacific using registry data and explored its association with survival outcomes. A total of 2374 patients with a median follow-up time of 29.5 months (interquartile range 13.3-54.3 months) were included in the analysis - 1673 from Australia, 313 Korea, 281 New Zealand and 107 Singapore. Overall, 7.1% of participants received immunoglobulin replacement within 24 months of diagnosis. Patients who received immunoglobulin replacement 2024-01-01T00:00:00Z2024 Aug2025-04-19T14:50:30.802Z2025-04-19T14:50:30.802ZS-EPMC113277093915759210.1002/jha2.938